American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Humacyte stock may fail to sustain today’s gains: find out more

by admin December 21, 2024
December 21, 2024
Humacyte stock may fail to sustain today’s gains: find out more

Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA).

Regulatory approval for the company’s bioengineered human tissue marks a major step forward in regenerative medicine and trauma care.

Humacyte stock sure has made its investors a happy lot today – but a more important question is: would it be able to sustain its recent gains heading into the next year?

Unfortunately, there’s reason to believe it may not.  

Insiders have been unloading Humacyte stock

Recent insider moves have not been particularly encouraging in Humacyte.

Brady W. Dougan – its board member who’s married to chief executive Laura Niklason sold a total of 1.5 million shares of Humacyte via his LLC called Ayabudge for $6.6 million in November.   

Insider selling is often considered negative because it signals a lack of confidence in the company’s future prospect.

That’s because executives and board members usually have more information than an average investor.

So, when they trim or sell their stake entirely, it typically suggests they see the stock as overvalued or expect the company to face challenges ahead.

If any of those assumptions prove true, Humacyte stock may end up losing today’s gain over the next few weeks.

HUMA is yet to turn a quarterly revenue

FDA’s approval for Humacyte’s SYMVESS sure is a big news for regenerative medicine.

But one must not forget that it continues to be a pre-revenue company for now. Humacyte lost $39.2 million in its third financial quarter – a significant increase from $26 million a year ago.

The Nasdaq listed firm ended its Q3 with $71 million in cash, cash equivalents, and restricted cash, which suggests it may have to dilute its shareholders to fund operations moving forward.  

What’s also worth mentioning is that Humacyte stock was worth about $3.0 before today’s gain.

So, there’s possibility that investors are manipulating its modest price tag to pump it up before unloading all of it to lock in sizeable profits.

Humacyte faces litigation for misleading investors

Finally, Humacyte is currently grappling with a class-action lawsuit over allegedly misleading investors about the regulatory compliance of its production facilities.

The biotech firm has failed to share critical information with its investors about its business and operations.

If such allegations prove to be true, “the company’s conduct constitutes a serious violation of securities laws,” as per Reed Kathrein of Hagens Berman – a law firm investigating the matter.

And it’s not like Humacyte stock pays a dividend to reward its shareholders for their patience through the turbulence.

Nonetheless, Wall Street has a consensus “buy” rating on Humacyte shares with price targets going as high as $25 at writing.

The post Humacyte stock may fail to sustain today’s gains: find out more appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Why Nike’s CEO believes turnaround efforts could hurt in the short term
next post
Novo Nordisk stock just tanked 25%: here’s what happened

Related Posts

Coinbase stock nears death cross; Base Blockchain could...

September 14, 2024

Pernod Ricard, Remy, and other alcohol stocks fall...

March 14, 2025

Where are low-cost airlines cutting back now? New...

September 3, 2024

Consumers await key inflation data as hopes for...

February 14, 2024

BXMT: Is Blackstone Mortgage Trust a good dividend...

October 26, 2024

Indian markets close: Sensex, Nifty log sixth straight...

April 22, 2025

Trent shares are down 22% in Jan after...

January 24, 2025

Long VOXX: Voxx International Soars After Positive Earnings...

October 14, 2024

Walmart launches new grocery brand as it tries...

May 2, 2024

S&P 500 turns negative for 2025 as Trump’s...

March 5, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • GMS stock jumps 29% on takeover interest from Home Depot, QXO, analysts raise PTs

      June 22, 2025
    • Japan’s rice price surge: what’s driving it and why it could spark a political crisis

      June 22, 2025
    • BofA raises STOXX 600 target amid resilient global growth, warns on Mideast risks

      June 22, 2025
    • Palantir co-founder: US must prevent Iranian nukes

      June 22, 2025
    • Fed governor Waller advocates for July rate cut amid tariff, labor market outlook

      June 21, 2025

    Categories

    • Business (3,199)
    • Investing (2,531)
    • Latest News (2,000)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved